Positive results in Panacos’ HIV drug trial
The study met its primary endpoint by demonstrating a statistically significant reduction in the level of HIV in the blood, known as viral load, compared to placebo. The
China-based Biocytogen Pharmaceuticals has entered a non-exclusive licensing agreement with Qilu Pharmaceutical for a fully human VHH antibody molecule.
The application, which was filed on schedule, includes clinical data from a previously announced phase III trial demonstrating superiority of anidulafungin versus fluconazole in invasive candidiasis/candidemia. Anidulafungin is